Singapore Exchange (SGX) has completed the divestment of its wholly owned subsidiary, Scientific Beta, marking a strategic shift in the exchange’s portfolio.
The sale of the index provider allows the group to streamline operations and concentrate resources on its core market infrastructure and growth initiatives.
The move coincides with a significant recovery in capital-raising activity on the platform.
SGX is on track for a substantial rebound in initial public offerings, with projections indicating up to 30 new listings in 2026 if current market conditions persist.
As of late May, five companies had already completed their debuts, signaling early momentum in the pipeline.
This strategic realignment underscores SGX’s focus on capturing value from the resurgence in equity issuance.